Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 69 articles:
HTML format
Text format



Single Articles


    October 2018
  1. VAISHAMPAYAN U, Podgorski I, Heilbrun LK, Lawhorn-Crews JM, et al
    Biomarkers and Bone Imaging Dynamics associated with Clinical outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-1473.
    PubMed     Text format     Abstract available


  2. GARRIDO MF, Martin NJ, Bertrand M, Gaudin C, et al
    Regulation of eIF4F translation initiation complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-0704.
    PubMed     Text format     Abstract available


  3. PAKARAINEN T, Nevalainen J, Talala K, Taari K, et al
    The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC).
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1807.
    PubMed     Text format     Abstract available


  4. TAGAWA ST, Antonarakis ES, Gjyrezi A, Galletti G, et al
    Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY.
    Clin Cancer Res. 2018 Oct 9. pii: 1078-0432.CCR-18-0320.
    PubMed     Text format     Abstract available


  5. FLORES-MORALES A, Bergmann TB, Lavallee C, Batth TS, et al
    Proteogenomic characterization of patient-derived xenografts highlights the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer.
    Clin Cancer Res. 2018 Oct 1. pii: 1078-0432.CCR-18-0729.
    PubMed     Text format     Abstract available


    September 2018
  6. NAVA RODRIGUES D, Casiraghi N, Romanel A, Crespo M, et al
    RB1 Heterogeneity in Advanced Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 26. pii: 1078-0432.CCR-18-2068.
    PubMed     Text format     Abstract available


  7. BELTRAN H, Oromendia C, Danila DC, Montgomery B, et al
    A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.
    Clin Cancer Res. 2018 Sep 19. pii: 1078-0432.CCR-18-1912.
    PubMed     Text format     Abstract available


  8. GAO X, Dai C, Huang S, Tang J, et al
    Functional silencing of HSD17B2 in prostate cancer promotes disease progression.
    Clin Cancer Res. 2018 Sep 18. pii: 1078-0432.CCR-18-2392.
    PubMed     Text format     Abstract available


  9. FERRARI AC, Alumkal JJ, Stein MN, Taplin ME, et al
    Epigenetic Therapy with Panobinostat Combined with Bicalutamide Re-challenge in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-1589.
    PubMed     Text format     Abstract available


  10. DE LAERE B, Oeyen S, Mayrhofer M, Whitington T, et al
    TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2018 Sep 12. pii: 1078-0432.CCR-18-1943.
    PubMed     Text format     Abstract available


  11. ZHANG T, George DJ, Armstrong AJ
    Precision medicine approaches when prostate cancer Akts up.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-2491.
    PubMed     Text format     Abstract available


  12. KULARATNE SA, Thomas M, Myers CH, Gagare P, et al
    Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery for Prostate Cancer.
    Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-0803.
    PubMed     Text format     Abstract available


  13. ROSATI R, Polin LA, Ducker C, Li J, et al
    Strategy for Tumor Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
    Clin Cancer Res. 2018 Sep 5. pii: 1078-0432.CCR-18-0982.
    PubMed     Text format     Abstract available


  14. SIPEKY C, Gao P, Zhang Q, Wang L, et al
    Synergistic interaction of HOXB13 and CIP2A predispose to aggressive prostate cancer.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-0444.
    PubMed     Text format     Abstract available


  15. MOSTAGHEL EA, Zhang A, Hernandez S, Marck B, et al
    Contribution of Adrenal Glands to Intra-tumor Androgens and Growth of Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-1431.
    PubMed     Text format     Abstract available


    August 2018
  16. GRUBMULLER B, Baltzer PA, Hartenbach S, D'Andrea D, et al
    PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact.
    Clin Cancer Res. 2018 Aug 23. pii: 1078-0432.CCR-18-0768.
    PubMed     Text format     Abstract available


  17. LAMBROS MB, Seed G, Sumanasuriya S, Gil V, et al
    Single Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-0862.
    PubMed     Text format     Abstract available


  18. GANAIE A, Beigh FH, Astone M, Ferrari MG, et al
    BMI1 drives metastasis of prostate cancer in Caucasian and African-American men and is a potential therapeutic target: hypothesis tested in race-specific models.
    Clin Cancer Res. 2018 Aug 7. pii: 1078-0432.CCR-18-1394.
    PubMed     Text format     Abstract available


  19. BARBER LE, Gerke T, Markt SC, Peisch SF, et al
    Family history of breast or prostate cancer and prostate cancer risk.
    Clin Cancer Res. 2018 Aug 6. pii: 1078-0432.CCR-18-0370.
    PubMed     Text format     Abstract available


  20. BOYSEN G, Nava Rodrigues D, Rescigno P, Seed G, et al
    SPOP mutated/ CHD1 deleted lethal prostate cancer and abiraterone sensitivity.
    Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-0937.
    PubMed     Text format     Abstract available


    July 2018
  21. IGLESIAS-GATO D, Thysell E, Tyanova S, Crnalic S, et al
    The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications.
    Clin Cancer Res. 2018 Jul 24. pii: 1078-0432.CCR-18-1229.
    PubMed     Text format     Abstract available


  22. DE BONO JS, De Giorgi U, Nava Rodrigues D, Massard C, et al
    Randomized Phase II Study of Akt Blockade With or Without Ipatasertib in Abiraterone-Treated Patients With Metastatic Prostate Cancer With and Without PTEN Loss.
    Clin Cancer Res. 2018 Jul 23. pii: 1078-0432.CCR-18-0981.
    PubMed     Text format     Abstract available


  23. TOREN P, Hoffman A, Ding K, Joncas FH, et al
    Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-1187.
    PubMed     Text format     Abstract available


  24. ARAI S, Jonas O, Whitman M, Corey E, et al
    Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0549.
    PubMed     Text format     Abstract available


  25. LIU Q, Tong D, Liu G, Gao J, et al
    Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-0420.
    PubMed     Text format     Abstract available


  26. GUPTA S, Nordquist LT, Fleming MT, Berry WR, et al
    Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-0564.
    PubMed     Text format     Abstract available


  27. TANG W, Wallace TA, Yi M, Magi-Galluzzi C, et al
    IFNL4-DeltaG allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-1060.
    PubMed     Text format     Abstract available


    June 2018
  28. ANTONARAKIS ES, Small EJ, Petrylak D, Quinn DI, et al
    Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association With Overall Survival.
    Clin Cancer Res. 2018 Jun 1. pii: 1078-0432.CCR-18-0638.
    PubMed     Text format     Abstract available


    May 2018
  29. BLEE AM, He Y, Yang Y, Ye Z, et al
    TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-18-0653.
    PubMed     Text format     Abstract available


  30. HAYASHI T, Fujita K, Nojima S, Hayashi Y, et al
    High-fat Diet-induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling.
    Clin Cancer Res. 2018 May 18. pii: 1078-0432.CCR-18-0106.
    PubMed     Text format     Abstract available


  31. ALSHALALFA M, Karnes RJ, Sharma V, Choeurng V, et al
    Development and validation of a prostate cancer genomic signature that predicts early ADT treatment response following radical prostatectomy.
    Clin Cancer Res. 2018 May 14. pii: 1078-0432.CCR-17-2745.
    PubMed     Text format     Abstract available



  32. Correction: Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
    Clin Cancer Res. 2018;24:2234.
    PubMed     Text format    


  33. BHANVADIA RR, VanOpstall C, Brechka H, Barashi NS, et al
    MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.
    Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3673.
    PubMed     Text format     Abstract available


    April 2018
  34. HUANG H, Wang C, Liu F, Li HZ, et al
    Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0461.
    PubMed     Text format     Abstract available


  35. SHIH TC, Liu R, Wu CT, Li X, et al
    Targeting Galectin-1 impairs castration-resistant prostate cancer progression and invasion.
    Clin Cancer Res. 2018 Apr 17. pii: 1078-0432.CCR-18-0157.
    PubMed     Text format     Abstract available


  36. GORDEVICIUS J, Krisciunas A, Groot DE, Yip SM, et al
    Cell-free DNA modification dynamics in abiraterone acetate-treated prostate cancer patients.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0101.
    PubMed     Text format     Abstract available


    March 2018
  37. SCROGGINS B, Matsuo M, White A, Saito K, et al
    Hyperpolarized [1-(13)C]-pyruvate magnetic resonance spectroscopic imaging of prostate cancer in vivo predicts efficacy of targeting the Warburg effect.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1957.
    PubMed     Text format     Abstract available


  38. WELTI J, Sharp A, Yuan W, Dolling DI, et al
    Targeting bromodomain and extra-terminal (BET) family proteins in castration resistant prostate cancer (CRPC).
    Clin Cancer Res. 2018 Mar 19. pii: 1078-0432.CCR-17-3571.
    PubMed     Text format     Abstract available


    February 2018
  39. MARANTO C, Udhane V, Hoang DT, Gu L, et al
    STAT5A/B BLOCKADE SENSITIZES PROSTATE CANCER TO RADIATION THROUGH INHIBITION OF RAD51 AND DNA REPAIR.
    Clin Cancer Res. 2018 Feb 26. pii: 1078-0432.CCR-17-2768.
    PubMed     Text format     Abstract available


  40. HECK MM, Retz M, Bandur M, Souchay M, et al
    Molecular lymph node status for prognostic stratification of prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-3771.
    PubMed     Text format     Abstract available


  41. KIM K, Watson PA, Lebdai S, Jebiwott S, et al
    Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-3474.
    PubMed     Text format     Abstract available


    November 2017
  42. WANG C, Peng G, Huang H, Liu F, et al
    Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-2446.
    PubMed     Text format     Abstract available


  43. YANG Y, Bai Y, He Y, Zhao Y, et al
    PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer.
    Clin Cancer Res. 2017 Nov 22. pii: clincanres.2006.2017.
    PubMed     Text format     Abstract available


  44. PUHR M, Hoefer J, Eigentler A, Ploner C, et al
    The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved anti-androgen therapy.
    Clin Cancer Res. 2017 Nov 20. pii: clincanres.0989.2017.
    PubMed     Text format     Abstract available


  45. BELDERBOS BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, et al
    Influence of Enzalutamide on Cabazitaxel Pharmacokinetics; a Drug-Drug Interaction Study in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients.
    Clin Cancer Res. 2017 Nov 17. pii: clincanres.2336.2017.
    PubMed     Text format     Abstract available


  46. ZHANG W, Liu B, Wu W, Li L, et al
    Targeting the MYCN-PARP-DNA Damage Response Pathway inNeuroendocrine Prostate Cancer.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.1872.2017.
    PubMed     Text format     Abstract available


  47. PALLER CJ, Zhou XC, Heath EI, Taplin ME, et al
    Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
    Clin Cancer Res. 2017 Nov 7. pii: clincanres.1100.2017.
    PubMed     Text format     Abstract available


    September 2017
  48. KALINA JL, Neilson DS, Lin YY, Hamilton PT, et al
    Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T cell Epitopes & Immune Signatures in a Subset of Prostate Cancer.
    Clin Cancer Res. 2017 Sep 27. pii: clincanres.0618.2017.
    PubMed     Text format     Abstract available


  49. LABBE DP, Sweeney CJ, Brown M, Galbo P, et al
    TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0413.2017.
    PubMed     Text format     Abstract available


  50. KETOLA K, Munuganti RS, Davies A, Nip KM, et al
    Targeting Prostate Cancer Subtype 1 by Forkhead box M1 Pathway Inhibition.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0901.2017.
    PubMed     Text format     Abstract available


  51. CALAGUA C, Russo J, Sun Y, Schaefer R, et al
    Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
    Clin Cancer Res. 2017 Sep 11. pii: clincanres.0807.2017.
    PubMed     Text format     Abstract available


    August 2017
  52. BELTRAN H, Wyatt AW, Chedgy E, Donoghue A, et al
    Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Clin Cancer Res. 2017 Aug 25. pii: clincanres.1034.2017.
    PubMed     Text format     Abstract available


  53. GUEDES L, Antonarakis ES, Schweizer MT, Mirkheshti N, et al
    MSH2 Loss in Primary Prostate Cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0955.2017.
    PubMed     Text format     Abstract available


    July 2017
  54. GAO WQ, Guo Y, Zhang K, Cheng C, et al
    Numb-/low enriches a castration resistant prostate cancer cell subpopulation associated with enhanced Notch and Hedgehog signaling.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0913.2017.
    PubMed     Text format     Abstract available


  55. SEED G, Yuan W, Mateo J, Carreira S, et al
    Gene Copy Number Estimation From Targeted Next Generation Sequencing Of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0972.2017.
    PubMed     Text format     Abstract available



  56. Retraction: GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.
    Clin Cancer Res. 2017;23:3973.
    PubMed     Text format    



  57. Correction: A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2017;23:3970.
    PubMed     Text format    


    June 2017
  58. BILUSIC M, Madan RA, Gulley JL
    Immunotherapy of Prostate Cancer: Facts and Hopes.
    Clin Cancer Res. 2017 Jun 29. pii: clincanres.0019.2017.
    PubMed     Text format     Abstract available


  59. XU L, Mao X, Guo T, Chan PY, et al
    The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis.
    Clin Cancer Res. 2017 Jun 14. pii: clincanres.3081.2016.
    PubMed     Text format     Abstract available


    May 2017
  60. BAN K, Feng S, Shao L, Ittmann M, et al
    RET signaling in prostate cancer.
    Clin Cancer Res. 2017 May 10. pii: clincanres.0528.2017.
    PubMed     Text format     Abstract available


  61. KOHLI M, Ho Y, Hillman DW, Van Etten JL, et al
    Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.
    Clin Cancer Res. 2017 May 4. pii: clincanres.0017.2017.
    PubMed     Text format     Abstract available


  62. MONTGOMERY B, Tretiakova MS, Joshua AM, Gleave ME, et al
    Neoadjuvant Enzalutamide Prior to Prostatectomy.
    Clin Cancer Res. 2017;23:2169-2176.
    PubMed     Text format     Abstract available


    April 2017
  63. GUEDES L, Almutairi F, Haffner MC, Rajoria G, et al
    Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.0257.2017.
    PubMed     Text format     Abstract available


  64. MOSTAGHEL EA, Cho E, Zhang A, Alyamani M, et al
    Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
    Clin Cancer Res. 2017 Apr 7. pii: clincanres.2245.2016.
    PubMed     Text format     Abstract available


  65. NIEUWEBOER AJ, de Graan AM, Hamberg P, Bins S, et al
    Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.
    Clin Cancer Res. 2017;23:1679-1683.
    PubMed     Text format     Abstract available


  66. NESBITT H, Byrne NM, Williams SN, Ming L, et al
    Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
    Clin Cancer Res. 2017;23:1797-1808.
    PubMed     Text format     Abstract available


    March 2017
  67. SUOMINEN MI, Fagerlund KM, Rissanen JP, Konkol YM, et al
    Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models.
    Clin Cancer Res. 2017 Mar 31. pii: clincanres.2955.2016.
    PubMed     Text format     Abstract available


    January 2017
  68. SINNOTT JA, Peisch SF, Tyekucheva S, Gerke T, et al
    Prognostic Utility of a New mRNA Expression Signature of Gleason Score.
    Clin Cancer Res. 2017;23:81-87.
    PubMed     Text format     Abstract available


    May 2016
  69. CHUA ML, Bristow RG
    Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or <I>Frenemy</I>?
    Clin Cancer Res. 2016 May 10. pii: clincanres.0381.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: